Zusammenfassung
Hintergrund
Bestimmte Arzneistoffe gelten als potenziell ungeeignet für geriatrische Patienten; auf ihren Einsatz sollte möglichst verzichtet werden. Potenziell inadäquate Medikationen (PIM) wurden zu unterschiedlichen PIM-Listen zusammengefasst. 2010 erschien die deutsche PRISCUS-Liste. Ziel der vorliegenden Untersuchung ist die Bewertung der PRISCUS-Liste im Vergleich mit internationalen PIM-Listen.
Material und Methoden
Basierend auf ausgewählten PIM-Listen (PRISCUS, STOPP/START, Beers) wurde die Medikation von 308 Patienten einer geriatrischen Rehabilitationsklinik auf PIM untersucht. Einschlusskriterium der Patienten war ein Alter von ≥ 65 Jahren.
Ergebnisse
Bezüglich ermittelter PIM unterlag die PRISCUS-Liste quantitativ den STOPP-Kriterien. Während des Aufenthalts erhielt jeder Patient durchschnittlich 1,2 PIM gemäß STOPP-Kriterien und 0,5 PIM nach der PRISCUS-Liste. Die geringste Anzahl lieferte die Beers-Liste (0,4 PIM).
Schlussfolgerung
Vom Einsatz der Beers-Liste sollte wegen der fehlenden Anpassung an den deutschen Arzneimittelmarkt abgesehen werden. Eine Anpassung der PRISCUS-Liste um diagnoseabhängige STOPP-Kriterien könnte dazu beitragen, Therapieerfolg und Arzneimitteltherapiesicherheit bei geriatrischen Patienten wesentlich zu verbessern.
Abstract
Background
Certain drugs are classified as potentially inappropriate medications (PIM) for the elderly. In 2010, the PRISCUS list was published, specifically designed for its applicability in the German pharmaceutical market. The aim of this study was to evaluate the PRISCUS list compared to international PIM lists.
Methods
Based on selected PIM lists (PRISCUS, STOPP/START, Beers), the medications of 308 patients at a clinic of geriatric rehabilitation were screened for PIMs. Applying START criteria, omission of indicated drug therapies was detected.
Results
Regarding the rate of PIM detection, the PRISCUS list was less sensitive than the application of STOPP criteria. While hospitalized, the mean number of administered PIMs per patient was 1.2 based on STOPP criteria and 0.5 based on the PRISCUS list. The lowest number of PIMs per patient was detected by applying the Beers list (0.4 PIMs).
Conclusion
The Beers list should not be used in the German pharmaceutical market. The amendment of diagnosis-related STOPP criteria to the PRISCUS list would be useful to significantly advance therapeutic success and drug safety in the elderly.
Literatur
Ackerman SJ, Knight T, Schein J et al (2004) Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California medicaid population. Consult Pharm 19:118–132
Azermai M, Elseviers M, Petrovic M et al (2011) Geriatric drug utilisation of psychotropics in Belgian nursing homes. Hum Psychopharmacol Clin Exp 26:12–20
Barry PJ, Gallagher P, Ryan C, O’Mahony D (2007) START (Screening Tool to Alert doctors to Right Treatment). An evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing 36:628–631
Beers MH (1997) Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med 157:1531–1536
Chitturi S, George J (2002) Hepatotoxicity of commonly used-drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 22:169–183
Clark RF, Wei EM, Anderson PO (1995) Meperidine: therapeutic use and toxicity. J Emerg Med 13:797–802
Fialová D, Topinková E, Gambassi G et al (2005)Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 293:1348–1358
Fick DM, Cooper JW, Wade W (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults-results of a US consensus panel of experts. Arch Intern Med 163:2716–2724
Gallagher P, Ryan C, Byrne S, O’Mahony D (2008) STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 46:72–83
Golden AG, Ma Q, Nair V et al (2010) Risk for fractures with centrally acting muscle relaxants: an analysis of a national medicare advantage claims database. Ann Pharmacother 44:1369–1375
Harirforoosh S, Jamali F (2009) Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 8:669–681
Holt S, Schmiedl S, Thürmann PA (2010) Potentiell inadäquate Medikation für ältere Menschen: die PRISCUS-Liste. Dtsch Arztebl Int 107:543–551
Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76
Kyle CJ, Petersen HE, Overø KF (1998) Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 8:147–153
Lader MH (1999) Limitations on use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 9(Suppl 6):399–405
Landi F, Onder G, Cesari M et al (2005) Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 60:622–626
Mangoni AA, Jackson SHD (2003) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14
Mitra R (2011) Adverse effects of corticosteroids on bone metabolism: a review. PMR 3:466–471
Montgomery P, Lilly J (2007) Insomnia in the elderly. Clin Evid 5(online):pii2302
Rhalimi M, Helou R, Jaecker P (2009) Medication use and increased risk of falls in hospitalized elderly patients: a retrospective, case-control study. Drugs Aging 26:847–852
Spanemberg L, Nogueira EL, Silva CT da et al (2011) High prevalence and prescription of benzodiazepines for elderly: data from psychiatric consultation to patients from an emergency room of a general hospital. Gen Hosp Psychiatry 33:45–50
Tinetti M (2003) Preventing falls in elderly persons. N Eng J Med 348:42–49
Vale N, Nordmann AJ, Schwartz GG et al (2011) Statins for acute coronary syndrome. Cochrane Database Syst Rev 6:CD006870
Van den Akker NM, Buntinx F, Knottnerus A (1996) Comorbidity or multimorbidity: what‚s in a name? A review of the literature. Eur J Gen Pract 2:65–70
Wehling M (2008) Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun? Ein neues Bewertungssystem: fit for the aged (FORTA). Dtsch Med Wochenschr 133:2289–2291
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Danksagung
Diese Untersuchung wurde von der Apothekerstiftung Westfalen-Lippe in Rahmen einer Projektförderung unterstützt.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siebert, S., Elkeles, B., Hempel, G. et al. Die PRISCUS-Liste im klinischen Test. Z Gerontol Geriat 46, 35–47 (2013). https://doi.org/10.1007/s00391-012-0324-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00391-012-0324-4
Schlüsselwörter
- Medikationsmanagement
- Inadäquate Verschreibung
- Unerwünschte Nebenwirkungen
- Ältere Patienten
- Geriatrisches Assessment